Major Investor Quietly Ramps Up Stake in Hemab Therapeutics

RA Capital Management reports Hemab Therapeutics common share purchase worth $159,036.30

Hemab Therapeutics files initial beneficial ownership statement for AI DEN-MAB LLC

Major Investor Quietly Makes a Power Move on Hemab Therapeutics Stock

RA Capital Management acquires Hemab Therapeutics common shares worth $1,263,246.58

AI Den-Mab Llc Reports 10.4% Stake in Hemab Therapeutics Holdings Inc as of May 4 - SEC Filing

Hemab Therapeutics director Laura Tadvalkar resigns from board

RA Capital Management acquires Hemab Therapeutics common shares worth $48.7 million

Hemab Therapeutics amends bylaws, ends stockholder action by written consent

Hemab Therapeutics IPO prices at $18, raises USD 346.7 million

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Stock Track | Hemab Therapeutics Soars 50% on First Trading Day After IPO Pricing

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM

BRIEF-Hemab Therapeutics Prices Upsized IPO Of 16,750,000 Shares At $18.00 Per Share

Hemab Therapeutics Holdings Inc - Prices IPO of 16,750,000 Shares at $18.00 per Share

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

Hemab Therapeutics Holdings Inc - Sees IPO of 15,000,000 Common Shares - SEC Filing

Biotech Firm Hemab Therapeutics Sets US IPO Target at Up to $212 Million

Hemab Therapeutics Launches Initial Public Offering

Hemab Therapeutics Holdings Inc - Launches IPO of 11,764,706 Common Shares - SEC Filing